PARP1, a much-studied target for cancer therapy, plays key roles in the DNA damage response (DDR) by covalently transferring ADP-ribose from NAD+ to a target substrate, generating ADP-ribosylation (ADPr).1 Here, PARP1 is linked to cancer.